Doctors from applicant hospitals are not allowed to participate in the deliberation committee for the super expensive drug, Soliris

Restriction is now placed for medical doctors the related hospital which applied for the insurance benefit of the paroxysmal nocturnal hemoglobinuria(PNH) treatment, Soliris Inj(eculizumab), not to be involved with voting for the deliberation committee.

Though, if necessary to provide new medical technology or information in the context of the deliberation, they are allowed to make statements ...